Interpreting the hype and pharmacology claims

John critiques the claimed tumor SN‑38 accumulation advantage of liposomal irinotecan and sets expectations.

Play episode from 03:53

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!